PMID- 20976076
OWN - NLM
STAT- MEDLINE
DCOM- 20110518
LR  - 20211020
IS  - 1110-7251 (Electronic)
IS  - 1110-7243 (Print)
IS  - 1110-7243 (Linking)
VI  - 2010
DP  - 2010
TI  - Investigation of antiangiogenic tumor therapy potential of microencapsulated 
      HEK293 VEGF165b producing cells.
PG  - 645610
LID - 10.1155/2010/645610 [doi]
LID - 645610
AB  - To investigate the antiangiogenic potential of encapsulated VEGF(1)(6)(5)b producing 
      HEK293 cells, Human Embryonic Kidney 293 (HEK293) cells were stably transfected 
      to produce VEGF(1)(6)(5)b. Then they were encapsulated in alginate-polylysine-alginate 
      (APA) microcapsules. VEGF(1)(6)(5)b productivity and viability of encapsulated cells 
      were analyzed and compared with the non-encapsulated cells. Results showed that 
      encapsulated cells proliferated and remained viable within the microcapsules 
      throughout the 28-day period of the experiment. The quantity of VEGF(1)(6)(5)b 
      increased from 6.5 +/- 1.2 mug/ml at day 13 to 13 +/- 0.96 mug/ml at day 16. Then it 
      gradually dropped to 5 +/- 1.2 mug/ml for the last 3 days period as measured at day 
      28. Production of VEGF(1)(6)(5)b from encapsulated and non-encapsulated cells was 
      similar. The effect of VEGF(1)(6)(5)b harvested from encapsulated cells on Human 
      Umbilical Vein Endothelial cells (HUVECs) proliferation were also examined.The 
      same inhibitory effects on HUVECs proliferation was seen when the cells were 
      incubated with a mixture of VEGF(1)(6)(5)b and a 2-fold VEGF(1)(6)(5)b or with VEGF(1)(6)(5)b and 
      2-fold excess VEGF(1)(6)(5)b released from encapsulated cells. Subcutaneous injection 
      of microencapsulated VEGF(1)(6)(5)b producing cells in tumor site of nude mice resulted 
      in the reduction of the number of vessels around the tumors.
FAU - Afkhami, Fatemeh
AU  - Afkhami F
AD  - Biomedical Technology and Cell Therapy Research Laboratory, Department of 
      Biomedical Engineering and Artificial Cells and Organs Research Center, Faculty 
      of Medicine, McGill University, 3775 University Street, Montreal, QC H3A2B4, 
      Canada.
FAU - Durocher, Yves
AU  - Durocher Y
FAU - Prakash, Satya
AU  - Prakash S
LA  - eng
GR  - MOP 64308/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101014
PL  - United States
TA  - J Biomed Biotechnol
JT  - Journal of biomedicine & biotechnology
JID - 101135740
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology/*therapeutic use
MH  - Animals
MH  - Biological Assay
MH  - Blotting, Western
MH  - Cell Shape/drug effects
MH  - Cell Survival/drug effects
MH  - *Drug Compounding
MH  - Enzyme-Linked Immunosorbent Assay
MH  - HEK293 Cells
MH  - Humans
MH  - Mice
MH  - Mice, Nude
MH  - Neoplasms/*blood supply/*drug therapy/pathology
MH  - Neovascularization, Pathologic/*drug therapy
MH  - Transfection
MH  - Vascular Endothelial Growth Factor A/*biosynthesis/metabolism
PMC - PMC2957143
EDAT- 2010/10/27 06:00
MHDA- 2011/05/19 06:00
PMCR- 2010/10/14
CRDT- 2010/10/27 06:00
PHST- 2010/06/05 00:00 [received]
PHST- 2010/08/25 00:00 [accepted]
PHST- 2010/10/27 06:00 [entrez]
PHST- 2010/10/27 06:00 [pubmed]
PHST- 2011/05/19 06:00 [medline]
PHST- 2010/10/14 00:00 [pmc-release]
AID - 10.1155/2010/645610 [doi]
PST - ppublish
SO  - J Biomed Biotechnol. 2010;2010:645610. doi: 10.1155/2010/645610. Epub 2010 Oct 
      14.